Clinical Trials Directory

Trials / Unknown

UnknownNCT04101448

Prevalence of Bronchiectasis in COPD Patients

Prevalence of and Prognostic Impact of Bronchiectasis in COPD Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Detailed description

The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Conditions

Interventions

TypeNameDescription
OTHERprevalencepercentage of bronchectasis in COPD and its effect as prognostic measure

Timeline

Start date
2019-09-30
Primary completion
2020-09-01
Completion
2020-09-30
First posted
2019-09-24
Last updated
2019-09-24

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04101448. Inclusion in this directory is not an endorsement.